research Evaluation of Serum Amyloid A3 in Young Adult Males with Early Onset of Androgenic Alopecia
Young men with early hair loss and high SAA3 levels are at higher risk for heart disease.
Search
for
Sort by
Research
330-360 / 1000+ resultsresearch Non‐ablative Er:YAG laser is an effective tool in the treatment arsenal of androgenetic alopecia
Non-ablative Er:YAG laser effectively treats hair loss with high patient satisfaction and no side effects.
research Phenolic profile of leaves obtained from autochthonous grapevine cultivars in Isparta Province of Türkiye
White grapevine leaves, especially 'Razaki', have high phenolic content, useful for health products.
research A CLINICAL STUDY OF GERIATRIC DERMATOSES
Older people in Kerala often have skin conditions, with dry skin being the most common, and certain skin issues are linked to high cholesterol and diabetes.
research Efficacy and safety of platelet rich plasma therapy in male androgenetic alopecia
Platelet-rich plasma therapy is more effective than minoxidil lotion for increasing hair count in men with hair loss, with mild side effects and high satisfaction.
research Hyperpigmentation in a child as a clue to chikungunya
Chikungunya can cause hyperpigmentation in children and should be considered in diagnosis.
research P44 The presentation of systemic erythematous lupus with Kikuchi-Fujimoto disease
A woman with lupus and Kikuchi-Fujimoto disease improved with treatment.
research 133 A young girl with lupus, recurrent pericardial effusion and cardiac tamponade
Adding colchicine stopped the girl's recurring heart issues caused by lupus.
research Editorial Comment
More biopsy cores and MRI before biopsy can improve prostate cancer detection.
research Abstract P5-21-05: ERALOP study: Post adjuvant FEC - docetaxel chemotherapy for early breast cancer: Hair regrowth in the real life
After chemotherapy for early breast cancer, 33.4% of patients had long-term significant hair loss, with some hair regrowth over time, but treatments for hair loss were largely ineffective.
research Skin Lesions in a Daclizumab-treated Patient with Multiple Sclerosis
A patient with multiple sclerosis developed skin reactions after Daclizumab treatment, requiring more data on the drug's effects.
research Adverse Effects and Safety of 5-alpha Reductase Inhibitors (Finasteride, Dutasteride): A Systematic Review.
5-alpha reductase inhibitors are generally safe but can cause sexual side effects and require patient education on risks.
research Discordant phenotype in monozygotic twins with mosaic trisomy 12p in lymphocytes
Identical twins had different symptoms because one had more cells with an extra chromosome fragment in different tissues.
research Finasteride: Middle-Age Cure-All for Alopecia and Benign Prostatic Hyperplasia?–Reply–II
Finasteride is beneficial for BPH but requires careful monitoring due to cancer risks.
research Association Between 5α-Reductase Inhibitors and Prostate Cancer Mortality
5α-reductase inhibitors may help with prostate cancer but could increase the risk of severe tumors, so careful use is advised.
research TRAPPED IN THE HYPOGLYCEMIA LOOP
Early advanced therapies are crucial for better survival in aggressive insulinoma cases.
research 54 Punch graftingtypesPunch Designs
New punch designs for hair transplants have expanded options for surgeons.
research MP44-04 TRENDS IN 5-ALPHA REDUCTASE INHIBITOR USE BEFORE AND AFTER THE FOOD AND DRUG ADMINISTRATION SAFETY WARNING
Prescriptions for 5-alpha reductase inhibitors dropped significantly after the FDA's safety warning, especially for men with benign prostatic hyperplasia.
research Posters Presented at the 19th Joint Meeting of the International Society of Dermatopathology, March 2–3, 2016, Hilton Crystal City at Washington Reagan National Airport, Arlington, Virginia, USA
The meeting showcased rare skin disease cases, highlighting the need for accurate diagnosis and treatment.
research Finasteride Doesn't Shorten Survival in Long-term Study
Finasteride is safe for long-term use in prostate cancer treatment.
research Finasteride: not guilty after all?
Finasteride reduces prostate cancer risk but may increase aggressive cancer risk slightly.
research Australian Hair and Wool Research Society Cutaneous Biology and Endocrinology Workshop
The workshop highlighted the genetic links and psychological impacts of hair loss and skin disorders.
research A new look at an old option in the treatment of early-stage prostate cancer: hormone therapy as an alternative to watchful waiting
Hormone therapy might be a proactive alternative to watchful waiting for early-stage prostate cancer, potentially improving survival without aggressive treatment downsides.
research Disruption of tubular Flcn expression as a mouse model for renal tumor induction
Disrupting the Flcn gene in mice causes early kidney cysts and tumors, which can be treated with rapamycin.
research Androgenetic alopecia and prostate cancer: findings from an Australian case-control study.
The conclusion is that there might be a link between certain types of baldness and prostate cancer, which could be due to shared hormonal pathways.
research Blinded, Randomized, Quantitative Grading Comparison of Minimally Invasive, Fractional Radiofrequency and Surgical Face-lift to Treat Skin Laxity
Surgical face-lifts are more effective, but fractional radiofrequency is a good, less invasive alternative for treating skin laxity.
research A pilot study for triple combination therapy with a low-fluence 1064 nm Q-switched Nd:YAG laser, hydroquinone cream and oral tranexamic acid for recalcitrant Riehl’s Melanosis
The combination therapy significantly improved Riehl’s melanosis in patients without serious side effects.
research Development and validation of the Brigham Eyelash Tool for Alopecia (BELA): A measure of eyelash alopecia areata
The Brigham Eyelash Tool for Alopecia (BELA) is a reliable way to measure eyelash loss in alopecia areata patients.
research Taxane-induced alopecia: A historical review of patients with ovarian or breast cancer treated with with paclitaxel, docetaxel or paclitaxel poliglumex
PPX causes much less hair loss than traditional taxanes.
research Phase II trial of paclitaxel poliglumex (CT-2103) in pre- and post-menopausal women on hormonal replacement therapy (HRT) with non-small cell lung cancer (NSCLC).
Further testing of paclitaxel poliglumex for this cancer treatment is not justified.